Hudson Bay Capital Management LP Boosts Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Hudson Bay Capital Management LP increased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 10.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 275,000 shares of the company's stock after purchasing an additional 25,000 shares during the quarter. Hudson Bay Capital Management LP's holdings in Takeda Pharmaceutical were worth $3,641,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Blair William & Co. IL lifted its holdings in shares of Takeda Pharmaceutical by 8.1% during the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock worth $162,000 after purchasing an additional 913 shares during the period. Sage Rhino Capital LLC lifted its holdings in Takeda Pharmaceutical by 14.9% in the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock valued at $157,000 after acquiring an additional 1,538 shares during the period. Aaron Wealth Advisors LLC lifted its holdings in Takeda Pharmaceutical by 7.2% in the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock valued at $331,000 after acquiring an additional 1,670 shares during the period. OLD Mission Capital LLC lifted its holdings in Takeda Pharmaceutical by 13.7% in the fourth quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock valued at $185,000 after acquiring an additional 1,687 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in Takeda Pharmaceutical by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock valued at $69,000 after acquiring an additional 1,770 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK traded up $0.11 during midday trading on Friday, hitting $14.11. 1,136,705 shares of the stock were exchanged, compared to its average volume of 1,911,866. The stock has a market cap of $44.88 billion, a P/E ratio of 35.26, a PEG ratio of 0.24 and a beta of 0.26. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.43. The company has a 50 day moving average price of $14.78 and a 200-day moving average price of $14.00.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The company had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. On average, research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.